-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Entering the last week of March, several pharmaceutical companies announced personnel changes
.
.
Zhao Ping, a well-known corporate executive, officially confirmed today that she has resigned from the position of general manager of CStone Pharmaceuticals Greater China and decided to join a start-up pharmaceutical company, Binuoji Bio, as the CEO
.
.
March 28 is Zhao Ping's last working day at CStone Pharmaceuticals.
It is understood that Zhao Ping also announced the news to CStone employees in the company's WeChat group on March 28 and said goodbye to everyone
.
It is understood that Zhao Ping also announced the news to CStone employees in the company's WeChat group on March 28 and said goodbye to everyone
.
Zhao Ping is a medical executive from a pharmaceutical company.
During her tenure at Cornerstone, Zhao Ping built a business team and operation system for Cornerstone from scratch, and promoted the launch of many new drugs.
Her reputation among employees has always been very good
.
During her tenure at Cornerstone, Zhao Ping built a business team and operation system for Cornerstone from scratch, and promoted the launch of many new drugs.
Her reputation among employees has always been very good
.
Before joining CStone, Zhao Ping served as President of Allergan China and General Manager of Bristol-Myers Squibb China.
During her tenure at Bristol-Myers Squibb, she promoted the development of the blockbuster PD-1 product Opdivo in mainland China.
listed
.
During her tenure at Bristol-Myers Squibb, she promoted the development of the blockbuster PD-1 product Opdivo in mainland China.
listed
.
After Zhao Ping left CStone, the current business team is temporarily in charge of CEO Jiang Ningjun.
It is understood that the successor of the general manager should also be announced in the near future, and he is also a familiar professional manager
.
It is understood that the successor of the general manager should also be announced in the near future, and he is also a familiar professional manager
.
Next, let’s talk about Pfizer.
Some time ago, Pfizer announced the new structure of the Oncology Division.
On March 28, Wang Yi of Pfizer’s China Oncology Division announced to employees that Chu Nan was appointed as the head of the digestive/urinary/hematological tumor treatment area.
to take effect
.
Some time ago, Pfizer announced the new structure of the Oncology Division.
On March 28, Wang Yi of Pfizer’s China Oncology Division announced to employees that Chu Nan was appointed as the head of the digestive/urinary/hematological tumor treatment area.
to take effect
.
Before joining Pfizer, Chu Nan was the vice president of marketing and medical affairs of Junshi Biosciences, responsible for the oncology product portfolio strategy and the internationalization strategy of innovative drugs.
Working in the field of disease
.
Working in the field of disease
.
Since the beginning of this year, Pfizer has also gathered many well-known managers in the industry, such as Wan Dingzhong and Zhang Jianhui, and also introduced Zhang Meng from the Internet medical field as the head of customer innovation
.
.
Simcere Pharmaceuticals, another local pharmaceutical company, also announced a personnel appointment on March 28, appointing Dr.
Danny Chen, former senior vice president of SciNeuro, as senior vice president of Simcere Pharmaceutical Group, responsible for promoting the company's translational science and neurological research and development work, as well as the establishment and management of the R&D team of the Beijing Innovation Center, to enhance Simcere's global R&D capabilities in the field of central nervous system therapy
.
Danny Chen, former senior vice president of SciNeuro, as senior vice president of Simcere Pharmaceutical Group, responsible for promoting the company's translational science and neurological research and development work, as well as the establishment and management of the R&D team of the Beijing Innovation Center, to enhance Simcere's global R&D capabilities in the field of central nervous system therapy
.
According to Simcere Pharma, before SciNeuro, he also worked in Pfizer (US) Neuroscience R&D Department and served as the head of the department for many years.
In the early days, he was the chief scientist of Purdue Pharmaceuticals.
During his career, he led the central nervous system.
He has multiple clinical development projects in the field of system (CNS) diseases, and has extensive experience in clinical translation, clinical development and registration application, internal/external licensing evaluation and promotion of cooperation
.
In the early days, he was the chief scientist of Purdue Pharmaceuticals.
During his career, he led the central nervous system.
He has multiple clinical development projects in the field of system (CNS) diseases, and has extensive experience in clinical translation, clinical development and registration application, internal/external licensing evaluation and promotion of cooperation
.
Among many well-known domestic companies, Simcere has undergone a major transformation in recent years.
The company used to have strong commercialization capabilities, but now it continues to make efforts in innovation and R&D, focusing on tumors , nervous system and autoimmunity.
In large areas, this momentum can be maintained, and the future can be expected
.
The company used to have strong commercialization capabilities, but now it continues to make efforts in innovation and R&D, focusing on tumors , nervous system and autoimmunity.
In large areas, this momentum can be maintained, and the future can be expected
.
Entering the last week of March, several pharmaceutical companies announced personnel changes
.
.
Zhao Ping, a well-known corporate executive, officially confirmed today that she has resigned from the position of general manager of CStone Pharmaceuticals Greater China and decided to join a start-up pharmaceutical company, Binuoji Bio, as the CEO
.
.
March 28 is Zhao Ping's last working day at CStone Pharmaceuticals.
It is understood that Zhao Ping also announced the news to CStone employees in the company's WeChat group on March 28 and said goodbye to everyone
.
It is understood that Zhao Ping also announced the news to CStone employees in the company's WeChat group on March 28 and said goodbye to everyone
.
Zhao Ping is a medical executive from a pharmaceutical company.
During her tenure at Cornerstone, Zhao Ping built a business team and operation system for Cornerstone from scratch, and promoted the launch of many new drugs.
Her reputation among employees has always been very good
.
During her tenure at Cornerstone, Zhao Ping built a business team and operation system for Cornerstone from scratch, and promoted the launch of many new drugs.
Her reputation among employees has always been very good
.
Before joining CStone, Zhao Ping served as President of Allergan China and General Manager of Bristol-Myers Squibb China.
During her tenure at Bristol-Myers Squibb, she promoted the development of the blockbuster PD-1 product Opdivo in mainland China.
listed
.
During her tenure at Bristol-Myers Squibb, she promoted the development of the blockbuster PD-1 product Opdivo in mainland China.
listed
.
After Zhao Ping left CStone, the current business team is temporarily in charge of CEO Jiang Ningjun.
It is understood that the successor of the general manager should also be announced in the near future, and he is also a familiar professional manager
.
It is understood that the successor of the general manager should also be announced in the near future, and he is also a familiar professional manager
.
Next, let’s talk about Pfizer.
Some time ago, Pfizer announced the new structure of the Oncology Division.
On March 28, Wang Yi of Pfizer’s China Oncology Division announced to employees that Chu Nan was appointed as the head of the digestive/urinary/hematological tumor treatment area.
to take effect
.
Some time ago, Pfizer announced the new structure of the Oncology Division.
On March 28, Wang Yi of Pfizer’s China Oncology Division announced to employees that Chu Nan was appointed as the head of the digestive/urinary/hematological tumor treatment area.
to take effect
.
Before joining Pfizer, Chu Nan was the vice president of marketing and medical affairs of Junshi Biosciences, responsible for the oncology product portfolio strategy and the internationalization strategy of innovative drugs.
Working in the field of disease
.
Working in the field of disease
.
Since the beginning of this year, Pfizer has also gathered many well-known managers in the industry, such as Wan Dingzhong and Zhang Jianhui, and also introduced Zhang Meng from the Internet medical field as the head of customer innovation
.
.
Simcere Pharmaceuticals, another local pharmaceutical company, also announced a personnel appointment on March 28, appointing Dr.
Danny Chen, former senior vice president of SciNeuro, as senior vice president of Simcere Pharmaceutical Group, responsible for promoting the company's translational science and neurological research and development work, as well as the establishment and management of the R&D team of the Beijing Innovation Center, to enhance Simcere's global R&D capabilities in the field of central nervous system therapy
.
Danny Chen, former senior vice president of SciNeuro, as senior vice president of Simcere Pharmaceutical Group, responsible for promoting the company's translational science and neurological research and development work, as well as the establishment and management of the R&D team of the Beijing Innovation Center, to enhance Simcere's global R&D capabilities in the field of central nervous system therapy
.
According to Simcere Pharma, before SciNeuro, he also worked in Pfizer (US) Neuroscience R&D Department and served as the head of the department for many years.
In the early days, he was the chief scientist of Purdue Pharmaceuticals.
During his career, he led the central nervous system.
He has multiple clinical development projects in the field of system (CNS) diseases, and has extensive experience in clinical translation, clinical development and registration application, internal/external licensing evaluation and promotion of cooperation
.
In the early days, he was the chief scientist of Purdue Pharmaceuticals.
During his career, he led the central nervous system.
He has multiple clinical development projects in the field of system (CNS) diseases, and has extensive experience in clinical translation, clinical development and registration application, internal/external licensing evaluation and promotion of cooperation
.
Among many well-known domestic companies, Simcere has undergone a major transformation in recent years.
The company used to have strong commercialization capabilities, but now it continues to make efforts in innovation and R&D, focusing on tumors , nervous system and autoimmunity.
In large areas, this momentum can be maintained, and the future can be expected
.
The company used to have strong commercialization capabilities, but now it continues to make efforts in innovation and R&D, focusing on tumors , nervous system and autoimmunity.
In large areas, this momentum can be maintained, and the future can be expected
.
Entering the last week of March, several pharmaceutical companies announced personnel changes
.
.
Zhao Ping, a well-known corporate executive, officially confirmed today that she has resigned from the position of general manager of CStone Pharmaceuticals Greater China and decided to join a start-up pharmaceutical company, Binuoji Bio, as the CEO
.
enterprise enterprise enterprise.
March 28 is Zhao Ping's last working day at CStone Pharmaceuticals.
It is understood that Zhao Ping also announced the news to CStone employees in the company's WeChat group on March 28 and said goodbye to everyone
.
It is understood that Zhao Ping also announced the news to CStone employees in the company's WeChat group on March 28 and said goodbye to everyone
.
Zhao Ping is a medical executive from a pharmaceutical company.
During her tenure at Cornerstone, Zhao Ping built a business team and operation system for Cornerstone from scratch, and promoted the launch of many new drugs.
Her reputation among employees has always been very good
.
During her tenure at Cornerstone, Zhao Ping built a business team and operation system for Cornerstone from scratch, and promoted the launch of many new drugs.
Her reputation among employees has always been very good
.
Before joining CStone, Zhao Ping served as President of Allergan China and General Manager of Bristol-Myers Squibb China.
During her tenure at Bristol-Myers Squibb, she promoted the development of the blockbuster PD-1 product Opdivo in mainland China.
listed
.
During her tenure at Bristol-Myers Squibb, she promoted the development of the blockbuster PD-1 product Opdivo in mainland China.
listed
.
After Zhao Ping left CStone, the current business team is temporarily in charge of CEO Jiang Ningjun.
It is understood that the successor of the general manager should also be announced in the near future, and he is also a familiar professional manager
.
It is understood that the successor of the general manager should also be announced in the near future, and he is also a familiar professional manager
.
Next, let’s talk about Pfizer.
Some time ago, Pfizer announced the new structure of the Oncology Division.
On March 28, Wang Yi of Pfizer’s China Oncology Division announced to employees that Chu Nan was appointed as the head of the digestive/urinary/hematological tumor treatment area.
to take effect
.
Some time ago, Pfizer announced the new structure of the Oncology Division.
On March 28, Wang Yi of Pfizer’s China Oncology Division announced to employees that Chu Nan was appointed as the head of the digestive/urinary/hematological tumor treatment area.
to take effect
.
Before joining Pfizer, Chu Nan was the vice president of marketing and medical affairs of Junshi Biosciences, responsible for the oncology product portfolio strategy and the internationalization strategy of innovative drugs.
Working in the field of disease
.
disease disease diseaseWorking in the field of disease
.
Since the beginning of this year, Pfizer has also gathered many well-known managers in the industry, such as Wan Dingzhong and Zhang Jianhui, and also introduced Zhang Meng from the Internet medical field as the head of customer innovation
.
.
Simcere Pharmaceuticals, another local pharmaceutical company, also announced a personnel appointment on March 28, appointing Dr.
Danny Chen, former senior vice president of SciNeuro, as senior vice president of Simcere Pharmaceutical Group, responsible for promoting the company's translational science and neurological research and development work, as well as the establishment and management of the R&D team of the Beijing Innovation Center, to enhance Simcere's global R&D capabilities in the field of central nervous system therapy
.
Danny Chen, former senior vice president of SciNeuro, as senior vice president of Simcere Pharmaceutical Group, responsible for promoting the company's translational science and neurological research and development work, as well as the establishment and management of the R&D team of the Beijing Innovation Center, to enhance Simcere's global R&D capabilities in the field of central nervous system therapy
.
According to Simcere Pharma, before SciNeuro, he also worked in Pfizer (US) Neuroscience R&D Department and served as the head of the department for many years.
In the early days, he was the chief scientist of Purdue Pharmaceuticals.
During his career, he led the central nervous system.
He has multiple clinical development projects in the field of system (CNS) diseases, and has extensive experience in clinical translation, clinical development and registration application, internal/external licensing evaluation and promotion of cooperation
.
In the early days, he was the chief scientist of Purdue Pharmaceuticals.
During his career, he led the central nervous system.
He has multiple clinical development projects in the field of system (CNS) diseases, and has extensive experience in clinical translation, clinical development and registration application, internal/external licensing evaluation and promotion of cooperation
.
Among many well-known domestic companies, Simcere has undergone a major transformation in recent years.
The company used to have strong commercialization capabilities, but now it continues to make efforts in innovation and R&D, focusing on tumors , nervous system and autoimmunity.
In large areas, this momentum can be maintained, and the future can be expected
.
tumor tumor tumor The company used to have strong commercialization capabilities, but now it continues to make efforts in innovation and R&D, focusing on tumors , nervous system and autoimmunity.
In large areas, this momentum can be maintained, and the future can be expected
.
